NCT06864585View on ClinicalTrials.gov

A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan

Not yet recruitingOBSERVATIONAL
Enrollment

59

Participants

Timeline

Start Date

March 15, 2026

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2029

Conditions
Infectious Diseases
Interventions
DRUG

Avibactam sodium/Ceftazidime hydrate

The recommended adult dosage is 2.5 g (0.5 g of avibactam and 2 g of ceftazidime) administered by intravenous infusion over a period of 2 hours 3 times daily. For peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess, Zavicefta should be co-administered with a metronidazole injection.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06864585 - A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan | Biotech Hunter | Biotech Hunter